The prescribing changes illustrate the growing concern over rising vancomycin minimum inhibitory concentrations of MRSA in hospitals. For example, a recent study identified a new strain of vancomycin-resistant MRSA that caused a bloodstream infection in a Brazilian patient. Despite these concerns, vancomycin remains the standard-of-care antibiotic for treating MRSA infections, DRG found.
DRG’s survey of 100 infectious disease specialists who treated a minimum of 10 MRSA patients in the last month also revealed the following three MRSA treatment trends:
• Hospital-acquired and community-acquired MRSA remain the two most concerning Gram-positive pathogens for infectious disease specialists
• More than half of ID specialists indicated they have increased the number of MRSA patients discharged on outpatient parenteral antibiotic therapy
• Three-quarters of ID specialists said they would prescribe Sivextro, the new MRSA drug from Cubist, over Pfizer’s Zyvox for treating MRSA skin infections
More Articles on MRSA:
Methicillin-Susceptible S. aureus Strains a Concern in Neonatal Care Settings
MRSA-Fighting Drug Approved by FDA
Updated Guidelines for Skin, Soft Tissue Infections From IDSA
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.